Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 446

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 15
Chunk 446
---
851)  (8,421,457)  -   (8,441,308)                 GROSS PROFIT  4,368   1,325,130   -   1,329,498                  OTHER INCOME  19,629   466,407   -   486,036                  OPERATING EXPENSES                Sales and marketing  (18,884)  (569,896)  (8,078)  (596,858)Research and development  (54,982)  -   -   (54,982)General and administrative  (171,881)  (134,678)  (2,136,296)  (2,442,855)Provision for expected credit losses   -   (1,314,427)  -   (1,314,427)TOTAL OPERATING EXPENSES  (245,747)  (2,019,001)  (2,144,374)  (4,409,122)                 LOSS FROM OPERATIONS  (221,750)  (227,464)  (2,144,374)  (2,593,588)                 FINANCE COSTS  (5,052)  (8,877)  -   (13,929)                 LOSS BEFORE TAX  (226,802)  (236,341)  (2,144,374)  (2,607,517)                 Deferred tax  12,269   5,090   -   17,359 Income tax  (2,613)  (36,272)  -   (38,885)Total tax (expense)/credit  9,656   (31,182)  -   (21,526)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(217,146) $(267,523) $(2,144,374) $(2,629,043)

 F-26Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE YEAR EN